annual operating expenses:
$1.02B+$61.23M(+6.39%)Summary
- As of today (September 16, 2025), RARE annual total operating expenses is $1.02 billion, with the most recent change of +$61.23 million (+6.39%) on December 31, 2024.
- During the last 3 years, RARE annual operating expenses has risen by +$302.34 million (+42.16%).
- RARE annual operating expenses is now at all-time high.
Performance
RARE Operating expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly operating expenses:
$242.76M-$1.82M(-0.74%)Summary
- As of today (September 16, 2025), RARE quarterly total operating expenses is $242.76 million, with the most recent change of -$1.82 million (-0.74%) on June 30, 2025.
- Over the past year, RARE quarterly operating expenses has increased by +$9.52 million (+4.08%).
- RARE quarterly operating expenses is now -19.92% below its all-time high of $303.14 million, reached on September 30, 2022.
Performance
RARE quarterly operating expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Operating expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
RARE Operating expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +6.4% | +4.1% |
| 3 y3 years | +42.2% | +10.9% |
| 5 y5 years | +96.5% | +102.7% |
RARE Operating expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +42.2% | -19.9% | +10.9% |
| 5 y | 5-year | at high | +96.5% | -19.9% | +102.7% |
| alltime | all time | at high | >+9999.0% | -19.9% | +5234.3% |
RARE Operating expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $242.76M(-0.7%) |
| Mar 2025 | - | $244.58M(-6.4%) |
| Dec 2024 | $1.02B(+6.4%) | $261.18M(+8.1%) |
| Sep 2024 | - | $241.70M(+3.6%) |
| Jun 2024 | - | $233.25M(-5.9%) |
| Mar 2024 | - | $247.80M(+4.4%) |
| Dec 2023 | $958.25M(-2.6%) | $237.39M(+2.3%) |
| Sep 2023 | - | $232.16M(-5.8%) |
| Jun 2023 | - | $246.35M(+3.6%) |
| Mar 2023 | - | $237.81M(-0.8%) |
| Dec 2022 | $983.93M(+37.2%) | $239.80M(-20.9%) |
| Sep 2022 | - | $303.14M(+38.5%) |
| Jun 2022 | - | $218.88M(+5.7%) |
| Mar 2022 | - | $207.08M(+15.7%) |
| Dec 2021 | $717.13M(+20.5%) | $178.91M(+9.0%) |
| Sep 2021 | - | $164.08M(+0.4%) |
| Jun 2021 | - | $163.49M(-17.2%) |
| Mar 2021 | - | $197.41M(+19.1%) |
| Dec 2020 | $595.02M(+14.7%) | $165.81M(+31.2%) |
| Sep 2020 | - | $126.34M(+5.5%) |
| Jun 2020 | - | $119.78M(-24.0%) |
| Mar 2020 | - | $157.63M(+28.4%) |
| Dec 2019 | $518.88M(+23.0%) | $122.77M(-11.7%) |
| Sep 2019 | - | $139.00M(+3.9%) |
| Jun 2019 | - | $133.75M(+16.5%) |
| Mar 2019 | - | $114.81M(+11.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2018 | $421.72M(+27.2%) | $103.15M(+6.6%) |
| Sep 2018 | - | $96.78M(-4.6%) |
| Jun 2018 | - | $101.47M(+0.7%) |
| Mar 2018 | - | $100.78M(+11.1%) |
| Dec 2017 | $331.55M(+33.6%) | $90.73M(+8.4%) |
| Sep 2017 | - | $83.71M(+8.2%) |
| Jun 2017 | - | $77.39M(+12.5%) |
| Mar 2017 | - | $68.79M(-2.5%) |
| Dec 2016 | $248.14M(+68.0%) | $70.55M(+7.2%) |
| Sep 2016 | - | $65.78M(+13.3%) |
| Jun 2016 | - | $58.05M(+9.4%) |
| Mar 2016 | - | $53.08M(-4.7%) |
| Dec 2015 | $147.74M(+160.2%) | $55.68M(+41.0%) |
| Sep 2015 | - | $39.49M(+32.2%) |
| Jun 2015 | - | $29.88M(+40.3%) |
| Mar 2015 | - | $21.30M(+27.3%) |
| Dec 2014 | $56.78M(+75.9%) | $16.73M(+7.0%) |
| Sep 2014 | - | $15.64M(+15.9%) |
| Jun 2014 | - | $13.50M(+32.1%) |
| Mar 2014 | - | $10.22M(+8.6%) |
| Dec 2013 | $32.28M(+101.9%) | $9.41M(+22.9%) |
| Sep 2013 | - | $7.66M(+15.6%) |
| Mar 2013 | - | $6.62M(+44.4%) |
| Dec 2012 | $15.98M(+143.6%) | $4.59M(+0.8%) |
| Sep 2012 | - | $4.55M |
| Dec 2011 | $6.56M | - |
FAQ
- What is Ultragenyx Pharmaceutical Inc. annual total operating expenses?
- What is the all time high annual operating expenses for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. annual operating expenses year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. quarterly operating expenses year-on-year change?
What is Ultragenyx Pharmaceutical Inc. annual total operating expenses?
The current annual operating expenses of RARE is $1.02B
What is the all time high annual operating expenses for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high annual total operating expenses is $1.02B
What is Ultragenyx Pharmaceutical Inc. annual operating expenses year-on-year change?
Over the past year, RARE annual total operating expenses has changed by +$61.23M (+6.39%)
What is Ultragenyx Pharmaceutical Inc. quarterly total operating expenses?
The current quarterly operating expenses of RARE is $242.76M
What is the all time high quarterly operating expenses for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high quarterly total operating expenses is $303.14M
What is Ultragenyx Pharmaceutical Inc. quarterly operating expenses year-on-year change?
Over the past year, RARE quarterly total operating expenses has changed by +$9.52M (+4.08%)